Founded on the basis of on their research into blood-based precision medicine, Adela seeks to further develop and commercialize a platform to detect multiple cancers, including kidney cancer and intracranial brain tumors, using a simple blood sample. This diagnostic test could ultimately diminish the need for biopsies, which can be invasive and result in more down time for patients.
“The immense potential of our core technology has already been demonstrated across 10 different cancer types,” says Dr. De Carvalho. “We took advantage of the fact that there are a large number of DNA methylation marks that are characteristic of circulating tumor DNA in the blood of cancer patients and using this knowledge, we developed a robust and cost-efficient approach to profile or ‘read’ DNA methylation in this circulating DNA, combining them with machine learning analysis.”
The result of their research is a highly sensitive test that can classify multiple solid tumours.
To date, Adela has received over $60M USD in funding from investors, including F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, and RA Capital Management.
Please join the Department of Medical Biophysics in congratulating Dr. Bratman and Dr. De Carvalho on this outstanding achievement!
